Development of a Multimodal AI System for GIST Management

Plain-language summary

This study examined the development of a multimodal artificial intelligence analysis system to help evaluate patients with gastrointestinal stromal tumor (GIST). Patients aged 18 and older with a gastric submucosal tumor or suspected GIST who were scheduled for surgery or endoscopic biopsy and had a contrast-enhanced CT before surgery took part. It is a study with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Qun Zhao

Intervention

Multimodal AI Analysis System

Start date

1/1/2024

Estimated completion

1/1/2026

Countries

China

Related genes

Locations

• Fuyang, China
• Baoding, China
• Cangzhou, China
• Hengshui, China
• Shijiazhuang, China
• Xingtai, China
• Wuhan, China
• Hengyang, China
• Nanjing, China

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

Age ≥ 18 years, gender not limited.

Clinical diagnosis of gastric submucosal tumor (SMT) or suspected gastrointestinal stromal tumor (GIST) based on gastroscopy or ultrasound.

Scheduled for surgical resection or endoscopic biopsy at the study center.

Standard preoperative contrast-enhanced CT scans are available (performed within 2 weeks prior to surgery).

Patients or their legal guardians have signed the informed consent form.

Exclusion Criteria:

Received neoadjuvant therapy (e.g., Imatinib, chemotherapy, or radiotherapy) prior to surgery/biopsy.

Poor quality of CT images (e.g., severe motion artifacts) affecting radiomics analysis.

Insufficient tissue samples for pathological diagnosis or genetic testing.

Confirmed diagnosis of other primary malignancies.

Incomplete clinical data or lost to follow-up immediately after surgery.